Table 1.
Characteristics and Outcomes of Patients with and without Multi Drug Resistant Organisms (MDRO)
| Total Patients (n= 376) | MDRO (n=202) | Non-MDRO (n=174) | P-value | |
|---|---|---|---|---|
| Age (years), | 0.003 | |||
| Mean (SD*) | 60.5 (15.1) | 60.1 (15.4) | 61.7 (14.8) | |
| Median (range) | 62 (18–91) | 62 (20–88) | 62 (18–91) | |
| Gender, female, n (%) | 234 (62.2) | 113 (55.9) | 121 (69.5) | 0.007 |
| Type of malignancy | 0.047 | |||
| Solid, n (%) | 330 (87.8) | 171 (84.7) | 159 (91.4) | |
| Breast cancer | 85 (26) | 38 (22) | 47 (30) | |
| Gastrointestinal cancer | 60 (18) | 31 (18) | 29 (18) | |
| Bladder cancer | 55 (17) | 40 (23) | 15 (9) | |
| Prostate cancer | 33 (10) | 20 (12) | 13 (8) | |
| Lung cancer | 16 (5) | 9 (5) | 7 (4) | |
| Others | 81 (24) | 33 (20) | 48 (31) | |
| Hematological, n (%) | 46 (12.2) | 31 (15.3) | 15 (8.6) | |
| Multiple myeloma | 11 (24) | 7 (23) | 4 (26) | |
| Diffuse large B-cell lymphoma | 6 (13) | 5 (16) | 1 (7) | |
| Acute myeloid leukemia | 5 (11) | 4 (13) | 1 (7) | |
| Others | 24 (52) | 15 (48) | 9 (60) | |
| Metastatic solid tumor, n (%) | 170 (45.2) | 88 (43.6) | 82 (47.1) | 0.882 |
| Presence of comorbidities, n (%) | 249 (66.2) | 132 (65.3) | 117 (67.2) | 0.698 |
| Neutropenia (<500) upon culture collection, n (%) | 10 (2.7) | 6 (3.0) | 4 (2.3) | 0.754 |
| Thrombocytopenia (<100) upon culture collection, n (%) | 26 (6.9) | 15 (7.4) | 11 (6.3) | 0.605 |
| Presence of fever upon culture collection, n (%) | 45 (12.0) | 23 (11.4) | 22 (12.6) | 0.733 |
| Leukocyte esterase count, n (%) | <0.001 | |||
| 0 | 66 (17.6) | 31 (15.3) | 35 (20.1) | |
| 1 | 45 (12.0) | 20 (9.9) | 25 (14.4) | |
| 2 | 68 (18.0) | 41 (20.3) | 27 (15.5) | |
| 3 | 162 (43.0) | 84 (41.6) | 78 (44.8) | |
| WBC in urine analysis, n (%) | 0.673 | |||
| ≤ 50 | 195 (51.9) | 102 (50.5) | 93 (53.4) | |
| > 50 | 146 (38.8) | 74 (36.6) | 72 (41.4) | |
| Presence of indwelling urinary catheter within past 48 hours, n (%) | 75 (20.0) | 45 (22.3) | 30 (17.2) | 0.138 |
| Presence of nephrostomy, n (%) | 51 (13.6) | 32 (15.8) | 19 (10.9) | 0.157 |
| History of positive urine culture within the past 6 months, n (%) | 121 (32.2) | 83 (41.1) | 38 (21.8) | <0.001 |
| History of MDRO urine culture within the past 6 months, n (%) | 83 (22.1) | 72 (35.6) | 11 (6.3) | <0.001 |
| History of febrile neutropenia within past 3 months, n (%) | 13 (3.5) | 11 (5.4) | 2 (1.1) | N/A** |
| History of chemotherapy within past 3 months, n (%) | 171 (45.5) | 83 (41.1) | 88 (50.6) | 0.066 |
| History of long-term steroids within past 3 months, n (%) | 118 (31.4) | 57 (28.2) | 61 (35.1) | 0.154 |
| History of antibiotic use in past 3 months, n (%) | 239 (63.7) | 140 (69.3) | 99 (56.9) | 0.013 |
| History of hospitalization within past 3 months, n (%) | 187 (49.7) | 113 (56.0) | 74 (42.5) | 0.010 |
| History of ICU admission within past 3 months, n (%) | 22 (5.9) | 13 (6.4) | 9 (5.2) | 0.587 |
| 30 days mortality, n (%) | 47 (12.5) | 27 (13.4) | 20 (11.5) | N/A** |
| 90 days mortality, n (%) | 93 (24.7) | 56 (27.7) | 37 (21.3) | N/A** |
Abbreviations: *SD, standard deviation; **N/A, not available.